Evusheld reduces risk of symptomatic COVID-19 in high-risk population

Phase III trial shows Evusheld (tixagevimab and cilgavimab) reduces the risk of developing symptomatic COVID-19 in vulnerable populations. 

Related Keywords

Colorado ,United States ,Myron Levin ,Astrazeneca ,University Of Colorado School Medicine ,Provent Phase ,Colorado School ,Executive Vice President ,